Drug Profile
Thrombin - Angiotech Pharmaceuticals
Alternative Names: Hemaseel Thrombin; Human thrombin - Haemacure; Thrombin hemostatLatest Information Update: 24 Nov 2021
Price :
$50
*
At a glance
- Originator Haemacure Corporation
- Developer Angiotech Pharmaceuticals
- Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
- Mechanism of Action Thrombin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Haemorrhage
Most Recent Events
- 29 Mar 2012 Suspended - Preclinical for Haemorrhage in Canada (Topical)
- 07 Apr 2010 Angiotech Pharmaceuticals acquires certain assets of Haemacure Corporation, including its thrombin product
- 19 Aug 2009 Preclinical development is ongoing in Canada